renovia ace 10 mg/10 mg film - coated tablets
recordati ireland limited - Лерканидипин хидрохлорид, Эналаприла малеат - 10 mg/10 mg film - coated tablets
renovia ace 20 mg/10 mg film - coated tablets
recordati ireland limited - Лерканидипин хидрохлорид, Эналаприла малеат - 20 mg/10 mg film - coated tablets
viacoram 3,5 mg/2,5 mg tablets
les laboratoires servier - besilate амлодипина, Периндоприла аргинин - 3,5 mg/2,5 mg tablets
viacoram 7 mg/5 mg tablets
les laboratoires servier - besilate амлодипина, Периндоприла аргинин - 7 mg/5 mg tablets
renovia ace 20 mg/20 mg film - coated tablets
recordati ireland limited - Лерканидипин хидрохлорид, Эналаприла малеат - 20 mg/20 mg film - coated tablets
renovia 10 mg film - coated tablets
berlin-chemie ag (menarini group) - Лерканидипин - 10 mg film - coated tablets
renovia 20 mg film - coated tablets
berlin-chemie ag (menarini group) - Лерканидипин - 20 mg film - coated tablets
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - ривароксабан - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - Антитромботични агенти - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
brovarabies v-rg
САМ - БС ЕООД - Антиген Р-ТНА - блистер с антиген включен в ядлива примамка - 10 на 8 степен tcid50 - диви животни
zyclara
viatris healthcare limited - имиквимод - keratosis; keratosis, actinic - Антибиотици и химиотерапевтици за дерматологично приложение - zyclara е показан за локално лечение на клинично типични, non хиперкератотични, -Хипертрофична, видими или осезаеми актинични кератоза на Анфас или оплешивяване скалпа при имунокомпетентни възрастни, когато други възможности за локално лечение са противопоказан или по-малко подходящи.